Talus Bio's Gaelle Mercenne and Michelle Briscoe spent the day at the BYU Biotech Career Fair talking about the exciting work being done at Talus Bio and recruiting summer intern candidates.
Talus Bio
生物技术研究
Seattle，WA 3,560 位关注者
Gene regulator profiling in live cells for drug development
关于我们
Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs
- 网站
-
https://talus.bio
Talus Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Seattle，WA
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
550 17th Ave
Suite 550
US，WA，Seattle，98122
Talus Bio员工
-
Michelle Briscoe
Chief Operating Officer and Chief Financial Officer at Talus Bio | Co-founder & Board Member of OUTbio - Seattle ????? | Board Member of HBA -…
-
Stephen (Steve) Letrent
Chief Development Officer
-
Alex Federation
Co-Founder and CEO at Talus Bio - nothing is "undruggable" - therapeutics historically intractable transcription factors in cancer and beyond
-
Milad Alucozai
Early-stage Investor | Biotech & Healthcare Executive | Serial Entrepreneur | Scientist | Board Member
动态
-
Inspiring the next generation of Seattle’s female biotech leaders: Talus Bio co-founder and CTO, Lindsay Pino, is always generous with her time and expertise, and Nucleate Seattle is a wonderful organization to partner with to help support tomorrow’s bioentrepreneurs!
??Like attracts like??, and a few weeks ago Nucleate Seattle was excited to yet again support an opportunity for local female biotech leaders to network for an evening! This was out third women's dinner in Seattle, supported by Nucleate and Lyda Hill Philanthropies, which provides female trainees in #academia the chance to network with female leaders in the #biotech community. At this dinner, Lindsay Pino (Talus Bio) and Elizabeth Ruzzo, PhD (adyn) provided their time and experience as #startup founders to craft a memorable night! Along with everyone above, we want to thank and highlight the work by the Women Leading Life Sciences team and our own #leadership at Nucleate Seattle which helped make this possible! We are looking forward to hosting more events in the future, but keep an eye out, because space fills up fast!
-
-
Talus Bio 2025 Summer Internships - Open for Application Now! Talus Bio is seeking highly motivated summer interns to join our team next summer in our Data Science & Engineering group, our Drug Discovery group, and our Proteomics group! These paid summer internships provide opportunities to own and participate in challenging and impactful business-critical projects at a thriving pre-clinical biotech where we're targeting previously “undruggable” transcription factors to develop therapeutics for cancer and other diseases. Visit our website at https://talus.bio/careers/ to apply!
-
-
Talus Bio is hiring! We are looking for an LC-MS/Proteomics Sr. Research Associate to join us in building out our proteomics-driven drug discovery platform. Learn more at talus.bio/careers!
-
-
Take a peek behind the scenes with the team unlocking transcription factor therapeutics for cancer and beyond. Earlier this fall, the Talus Bio team gathered at our annual offsite to zero in on our big-picture strategy for 2025 and our constant north star: when the right team takes the reins, nothing is undruggable. Together, we’re recharged and geared up to ride into the year ahead.
-
"Open-source scientific software is not just a good idea; it’s a philosophy that embodies transparency, collaboration, and progress." This quote from the excellent article by our Head of Data Science and Engineering, William Fondrie, perfectly describes values that Talus Bio vigorous promotes and hopes to embody. Nice work, Will! https://lnkd.in/gKPpdF2x
-
Congratulations to Talus Bio co-founder and CTO, Lindsay Pino! The Human Proteome Organization honored Lindsay with the 2024 HUPO Rising Star Award. The award recognizes her contributions to the field of proteomics, from her research excellence and entrepreneurial spirit, to her educational and community-building efforts that have helped propel the field to the next wave of discovery. At Talus Bio, Lindsay is the driving force behind our MARMOT platform that leverages functional proteomics, automated biology, and machine learning to discover first-in-class treatments for cancer and diseases caused by transcription factor dysregulation. Join us in celebrating her accomplishments and this well-deserved recognition!
-
-
Thanks to Talus Bio board member, Omri Amirav-Drory from NFX, for this insightful blog post that clearly articulates the rationale behind the parallel business models of developing a platform and developing assets, because "great platforms should make great assets". We couldn't agree more!
My answer to the platform vs asset debate in techbio: Great platforms build great assets. But, you have to be strategic. It's about balance. You can advance a lead asset, while leveraging your platform (services, targets, other assets) to gain revenue + grow your platform. If you do it right, you create a cycle of growth. Our advice on striking this balance: https://lnkd.in/gVRxU7SU Quick examples below: Most companies fall somewhere on a continuum between monetizing the platform itself vs using assets to fuel platform development. Example: Twist Bioscience. They monetized a DNA synthesis platform and became a huge company. They pivoted toward assets later. But most bioplatforms aren't like that. Most need to pursue assets earlier to fuel development and show traction. Example: Mammoth Biosciences owns key IP in small CRISPR systems and has monetized various aspects of that IP through pharma deals. These partnerships boosted their credibility and funded future R&D. Now, they have strong pharma ties and millions in non-dilutive funding for internal development. My most recent essay tackles striking this balance, and what you need to show by Series A to be on the right track.
Why Great Bioplatforms Will Always Win
nfx.com
-
We're proud of Lindsay Pino's willingness to volunteer her time and expertise within the Skyline community! This is a great example of one of the many ways that Talus Bio's leadership team is giving back to fellow proteomics scientists.
Co-Founder and CTO at Talus Bio (YC S21) - nothing is undruggable - unlocking transcription factors with functional proteomics and genomics
Final day of Skyline Online Session 3, "Advanced Proteomics Topics", done! ? Big thanks to this session's instructors: Ariana Shannon, Juan Camilo Rojas Echeverri, Evan Hubbard, Alessio Di Ianni. Not only did they do a great job fielding questions from across the entire Skyline ecosystem, but also some really tough questions about sample preps, assay development, and experimental design. #TeamMassSpec #proteomics
-
-
Congratulations to our new Head of Biology, Gaelle Mercenne, for being featured in STAT's’ “Up & Down the Ladder.” We learned so much about her, for example, if she were a piece of lab equipment she’d be a plate shaker: "I want to know what is possible and what is not possible when considering drug targets, especially transcription factors. What is druggable? I love using new techniques to identify small molecules that inhibit previously considered undruggable targets. So the idea of being something to shake things up and challenging concepts and questions, it’s who I am.” At Talus Bio, we’ve got a lot of movers n’ shakers on the team–but only one Gaelle. Read the whole conversation with our newest team member in ed silverman's latest column, linked in comments (subscription required).
-